Approval · Notice of Compliance 2015 · 1999
NU-DIVALPROEX: Notice of Compliance 2015
Issued January 15, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2015
- Date
- January 15, 1999
- Company
- Nu-Pharm IncVaughan, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Anticonvulsant
- Canadian reference product
- EPIVAL (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NU-DIVALPROEX | 02239517 | Approved |
| NU-DIVALPROEX | 02239518 | Approved |
| NU-DIVALPROEX | 02239519 | Approved |
Medicinal ingredients
- DIVALPROEX SODIUM 125 MG per TAB
- DIVALPROEX SODIUM 250 MG per TAB
- DIVALPROEX SODIUM 500 MG per TAB